Hackman Jeffrey S. 4

What Happened
Jeffrey S. Hackman, Chief Executive Officer of Fennec Pharmaceuticals (FENC), acquired 1,159 shares on 2026-04-30 via an exercise/conversion of a derivative security (transaction code M). The reported transaction price was $0.00, yielding no cash outlay. The filing notes these shares were released from restrictions tied to an award granted on 2025-03-28 (footnote F1). This was an acquisition through vesting/release rather than an open-market purchase.

Key Details

• Transaction date: 2026-04-30; Filing date: 2026-05-01 (filed timely).
• Transaction type/code: M — Exercise or conversion of derivative security.
• Shares acquired: 1,159; Price per share: $0.00; Total cash paid: $0.
• Footnote: F1 — Shares released from restriction from shares awarded 3/28/2025.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context
An M-code transaction with a $0.00 price typically reflects conversion or release of previously granted equity (e.g., vested restricted stock or RSUs) rather than an open-market purchase. Such releases are common as part of compensation/vesting schedules and do not necessarily signal a discretionary buy or sell decision by the executive.